RxDoctor Payments Data

Joshua Kolmetz, MD

Internal Medicine · Crestview, FLNPI 1699862599

Payments from drug & device makers

$10,749in general payments, 2019–2025

Across 819 payments — averaging $13.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Amgen$1K
  • GSK$740
  • AbbVie$652
  • Lilly USA, LLC$652
  • Sanofi-aventis U.S. LLC$649
  • plus $4K from 48 others

What the payments were for

  • Food & beverage$10,740100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,749 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$830,101
Medicare patients
979
Services billed
13,313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide97$123,885
OzempicSemaglutide83$89,269
JardianceEmpagliflozin75$82,585
EliquisApixaban90$79,582
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$57,285
TrulicityDulaglutide34$52,139
XareltoRivaroxaban28$33,634
FarxigaDapagliflozin Propanediol25$31,654
RybelsusSemaglutide22$27,070
Repatha SureclickEvolocumab18$16,844
LinzessLinaclotide19$14,359
Janumet XrSitagliptin Phos/Metformin Hcl15$13,090
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$9,708
MyrbetriqMirabegron12$8,397
ShingrixVaricella-Zoster Ge/As01b/Pf38$8,206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$652$176,024131 claims
Novo NordiskOzempic, Rybelsus$2,649$116,338105 claims
Boehringer IngelheimJardiance, Spiriva Respimat$238$88,93787 claims
PfizerEliquis$439$79,58290 claims
GSKTrelegy Ellipta, Shingrix$740$65,49194 claims
Johnson & JohnsonXarelto$149$33,63428 claims
AstraZenecaFarxiga$438$31,65425 claims
AbbVieLinzess, Synthroid$652$16,30052 claims
MerckJanumet Xr$209$13,09015 claims
Astellas Pharma US IncMyrbetriq$21$8,39712 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$118$6,85711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Crestview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →